Study of APG2575 for CLL or SLL patients on BTKi
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called APG2575 for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have been taking a BTK inhibitor for at least 12 months. The goal is to see if adding APG2575 can help control the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have CLL or SLL that needs treatment and have been on a BTK inhibitor for at least 12 months.
- You must be in good enough health to carry out daily activities (ECOG score 0-2).
- Your blood counts must be within certain ranges (white blood cells, platelets, and hemoglobin) without needing growth factors or transfusions recently.
- Your kidney and liver function must be adequate based on blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies APG-2575 (alone or with other medicines) in adults with CLL/SLL whose disease came back or did not respond to earlier treatment. The goal is to learn the safest dose and whether it can shrink the leukemia and improve symptoms.
This trial tests a new drug, lisaftoclax (APG-2575), for people with certain slow-growing B-cell lymphomas. It's for those who haven't had treatment or can't take standard targeted therapy, or who had a targeted therapy but it didn't work well or caused serious side effects.
This trial tests a new combination of two targeted drugs (lisaftoclax and acalabrutinib) against standard chemo-immunotherapy for people newly diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma who need treatment. It aims to see if the combination works better.
This trial tests a new drug, lonitoclax, in people with certain B-cell blood cancers that have come back or not responded to earlier treatments. It aims to see if the drug can help control the disease.
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
This Phase 1/2 study tests APG2575 alone or combined with other treatment in people whose CLL/SLL has come back or did not respond to prior therapy. The goal is to see how well the treatment works and how safe it is.
Hear when a new CLL/SLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.